PDL Biopharma (PDLI) 8-K PDL Biopharma Announces Second Quarter 2006 Financial Results

Exhibit 99.1

Contact:

Ami Knoefler

Corporate and Investor Relations

(510) 284-8851

ami.knoefler@pdl.com

PDL BIOPHARMA ANNOUNCES SECOND QUARTER 2006 FINANCIAL RESULTS

– Second Quarter Revenues Up 29% Compared to Second Quarter 2005 –

Fremont, Calif., August 3, 2006 – PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter and the six months ended June 30, 2006:

• Total revenues for the second quarter of 2006 rose 29 percent to $104.3 million from $81.0 million in the same period of 2005.

• GAAP net loss was $6.1 million, or $0.05 per basic and diluted share, in the second quarter of 2006, compared with a GAAP net loss of $3.4 million, or $0.03 per basic and diluted share, in the second quarter of 2005.

• Non-GAAP net income rose 17 percent to $20.1 million, or $0.18 per basic and $0.17 per diluted share, for the second quarter of 2006, from non-GAAP net income of $17.1 million, or $0.16 per basic and diluted share, in the second quarter of 2005.

• Cash flow generated from operating activities for the first six months of 2006 was $43.6 million, compared to $2.4 million cash used in operating activities in the first six months of 2005.

“During the second quarter, we delivered solid overall revenue growth due to increased product sales and royalty revenue, breaking the $100 million mark in a quarter for the first time in our history. Our more diversified revenue stream, including our portfolio of three marketed products, is contributing to strong operating cash flow and reflects the fundamental shift we’ve made as a commercial company,” PDL BioPharma Chief Executive Officer Mark McDade said. “Despite the disappointing results from the terlipressin phase 3 study, we are advancing our other clinical programs and working to expand the pipeline with our antibody discovery and development activities.”

Revenues

Total revenues for the second quarter of 2006 included product sales, royalty revenues and license, collaboration and other revenues.

• Net product sales in the second quarter of 2006, which were comprised solely of Cardene IV, Retavase and IV Busulfex, were $39.0 million compared to $38.6 million in the same period in 2005, which also included $2.0 million in sales from four off-patent products. Net sales during the second quarter of 2006 were reduced by charges totaling $5.6 million related to a change in estimate during the quarter for product return reserves.

• Cardene IV sales were $24.4 million in the second quarter of 2006, a 46 percent increase from $16.7 million for the same period in 2005.

• Retavase sales were $8.1 million in the second quarter of 2006, a decrease from $14.0 million for the same period in 2005 due primarily to a decline in the thrombolytic market over this period.

• IV Busulfex sales were $6.6 million in the second quarter of 2006, a 12 percent increase from $5.9 million for the same period in 2005.

• Royalty revenues for the second quarter of 2006 increased 44 percent to $54.0 million compared with $37.5 million in the same three months of 2005. Royalty revenues during the second quarter of 2006 reflect royalties PDL received based on worldwide net sales of six antibody products licensed under PDL’s antibody humanization patents:Avastin™,Herceptin^®, Xolair^® and Raptiva^® from Genentech, Inc.;Synagis^® from MedImmune, Inc. andMylotarg^® from Wyeth.

• License, collaboration and other revenues during the second quarter of 2006 increased to $11.3 million from $4.9 million in the same period of 2005, primarily as a result of revenue recognized under the Biogen Idec and Roche collaborations, which were entered into in August 2005 and October 2005, respectively.

Costs and Expenses

Total costs and expenses were $111.8 million in the second quarter of 2006, compared with $83.5 million in the second quarter of 2005. On a non-GAAP basis, total costs and expenses in the second quarter of 2006 were $84.2 million compared to $63.9 million in the second quarter of 2005. Second quarter 2006 expenses increased as compared to the prior year due primarily to expanded clinical development activities for the company’s multiple pipeline products and increased selling, general and administrative expenses.

• Cost of product sales was $21.5 million in the second quarter of 2006 compared to $20.1 million in the same period in 2005. Non-GAAP cost of product sales, which excludes amortization of product rights, was $10.9 million in the second quarter of 2006, an increase from $8.2 million in the comparable 2005 period on the same basis. Cost of product sales during the second quarter of 2006 included an unanticipated $2.5 million charge related to analyzing and improving the Retavase manufacturing process with a contract manufacturer.

• Research and development (R&D) expenses increased to $61.9 million in the second quarter of 2006, compared with $40.3 million in the second quarter of 2005. On a non-GAAP basis, R&D expenses in the second quarter of 2006 were $51.0 million, an increase over the $36.4 million reported in the same period in the prior year. The increase reflected expanded clinical development activities associated with the ularitide, Nuvion and daclizumab programs.

• Selling, general and administrative (SG&A) expenses were $25.3 million during the second quarter of 2006, compared with $19.8 million in the second quarter of 2005. Non-GAAP SG&A expenses were $22.4 million compared to $19.2 million in the prior year comparable period. This increase was primarily due to a 48 percent increase in the company’s SG&A employee headcount, the majority of which was associated with the expansion of PDL’s hospital focused sales force and related sales and marketing personnel.

• Second quarter 2006 expenses included $5.6 million in stock-based compensation expense, a significant increase over the $0.2 million incurred in the same period in the prior year principally as a result of the adoption of Statement of Financial Accounting Standards (SFAS) No. 123(R) on January 1, 2006.

Balance Sheet and Cash Flows

At June 30, 2006, the company’s cash, cash equivalents, marketable securities and restricted investments totaled $414.3 million, an increase of $80.4 million compared to the balance at December 31, 2005. The June 30, 2006

balance reflected the receipt during the second quarter of 2006 of $31.7 million in cash related to the repayment of principal and accrued interest of a convertible promissory note. During the six months ended June 30, 2006, net cash provided by operating activities was $43.6 million, an increase from the $2.4 million net cash used in operating activities in the comparable prior year period.

Financial Outlook

PDL BioPharma is not updating its financial guidance as previously provided on May 2, 2006. Please refer to the press release available on the company’s website at www.pdl.com.

Non-GAAP Financial Information

The non-GAAP financial measures in this press release exclude depreciation of property and equipment, stock-based compensation expense, amortization of intangible assets, interest income and other, net, interest expense, income taxes and certain other items that would otherwise be included if measured in accordance with generally accepted accounting principles (GAAP). PDL’s management believes that these non-GAAP financial measures serve as a measure of the performance of PDL’s ongoing core operations. A description of the non-GAAP financial measures for the periods presented and a reconciliation of this information to the GAAP financial measures are included in the attached financial tables.

Forward-looking Statements

This press release contains forward-looking statements involving risks and uncertainties and PDL’s actual results may differ materially from those, express or implied, in the forward-looking statements. The forward-looking statements include PDL’s expectations regarding financial results, PDL’s expectations regarding the continuation of existing and new collaborative agreements, and the timing of clinical developments as well as other statements regarding PDL’s expectations. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The continued execution of a biopharmaceutical business model; changes in PDL’s development plans as PDL and its collaborators consider development plans and alternatives; factors affecting the clinical timeline such as enrollment rates and availability of clinical materials; fluctuations in sales that may result from PDL’s integration of newly acquired operations; changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses. In addition, PDL revenues depend on the success and timing of sales of PDL’s licensees, including in particular the continued success ofAvastin andHerceptin antibody products by Genentech, Inc. as well as the seasonality of sales ofSynagisfrom MedImmune, Inc. In addition, quarterly revenues may be impacted by PDL’s ability to maintain and increase its revenues from collaborative arrangements such as its co-development agreements with Biogen Idec and Roche. PDL’s net income will be affected by state and federal taxes, and its revenues and expenses would be affected by new collaborations, material patent licensing arrangements or other strategic transactions.

Further, there can be no assurance that results from completed and ongoing clinical studies will be successful or that ongoing or planned clinical studies will be completed or initiated on the anticipated schedules. Other factors that may cause PDL’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL’s filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” sections of its annual and quarterly reports filed with the SEC. Copies of PDL’s filings with the SEC may be obtained at the “Investors” section of PDL’s website at http://www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

About PDL BioPharma

PDL BioPharma, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses. The company currently markets and sells a portfolio of

leading products in the acute-care hospital setting in the United States and Canada and generates royalties through licensing agreements with top-tier biotechnology and pharmaceutical companies based on its pioneering antibody humanization technology. Currently, PDL’s diverse late-stage product pipeline includes six investigational compounds in Phase 2 or Phase 3 clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. The company’s research platform is focused on the discovery and development of antibodies for the treatment of cancer and autoimmune diseases. For more information, please see PDL’s website at www.pdl.com.

PDL BioPharma, the PDL BioPharma logo, Retavase and Busulfex are considered trademarks and Nuvion is a registered U.S. trademark of PDL BioPharma, Inc. Zenapax is a registered trademark of Roche. Cardene is a registered trademark of Hoffmann-La Roche. Herceptin and Raptiva are registered trademarks and Avastin is a trademark of Genentech, Inc. Xolair is a trademark of Novartis AG. Synagis is a registered U.S. trademark of MedImmune, Inc. Mylotarg is a registered U.S. trademark of Wyeth.

Financial tables attached

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2006			2005			2006			2005
REVENUES:
Product sales, net	$	39,039		$	38,552		$	76,586		$	39,500
Royalties		54,021			37,528			97,991			70,692
License, collaboration and other		11,264			4,888			20,959			9,591
Total revenues		104,324			80,968			195,536			119,783
COSTS AND EXPENSES:
Cost of product sales		21,482			20,135			44,441			21,272
Research and development		61,887			40,339			123,658			75,600
Selling, general and administrative		25,336			19,806			57,495			27,472
Acquired in-process research and development		—			—			—			79,417
Other acquisition-related charges		2,177			3,207			3,295			3,207
Asset impairment charge		900			—			900			—
Total costs and expenses		111,782			83,487			229,789			206,968
Operating loss		(7,458	)		(2,519	)		(34,253	)		(87,185	)
Interest income and other, net		4,064			1,873			7,394			4,808
Interest expense		(2,622	)		(2,709	)		(5,272	)		(4,851	)
Loss before income taxes		(6,016	)		(3,355	)		(32,131	)		(87,228	)
Income tax expense		118			65			233			87
Net loss	$	(6,134	)	$	(3,420	)	$	(32,364	)	$	(87,315	)
NET LOSS PER SHARE:
Basic and diluted	$	(0.05	)	$	(0.03	)	$	(0.29	)	$	(0.87	)
Weighted average shares — basic and diluted		113,539			103,705			113,006			100,230

In addition to the consolidated financial statements presented in accordance with GAAP, PDL uses non-GAAP measures of operating performance, which are adjusted from results based on GAAP to exclude depreciation of property and equipment; stock-based compensation expense; amortization of intangible assets; interest income and other, net; interest expense; income taxes and certain other miscellaneous items. PDL believes that the non-GAAP results provide added insight into its performance by focusing on results generated by its ongoing core operations. PDL uses the non-GAAP results when assessing the performance of its ongoing core operations, in making resource allocation decisions and for planning and forecasting. Additionally, PDL considers these non-GAAP results in awarding bonus and other incentive compensation to its employees, including management. The non-GAAP financial measures should be considered in addition to, not as a substitute for, or superior to, the measures of financial performance prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures.

PDL BIOPHARMA, INC.

NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS⁽¹⁾

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended June 30,				Six Months Ended June 30,
	2006		2005		2006		2005
REVENUES:
Product sales, net	$	39,039	$	38,552	$	76,586	$	39,500
Royalties		54,021		37,528		97,991		70,692
License, collaboration and other		11,264		4,888		20,959		9,591
Total revenues		104,324		80,968		195,536		119,783
COSTS AND EXPENSES:
Cost of product sales		10,917		8,230		23,311		8,307
Research and development		50,979		36,407		102,549		67,752
Selling, general and administrative		22,352		19,222		46,352		26,732
Non-GAAP costs and expenses		84,248		63,859		172,212		102,791
Non-GAAP net income	$	20,076	$	17,109	$	23,324	$	16,992
NON-GAAP NET INCOME PER SHARE:
Basic	$	0.18	$	0.16	$	0.21	$	0.17
Weighted average shares — basic		113,539		103,705		113,006		100,230
Diluted	$	0.17	$	0.16	$	0.20	$	0.17
Weighted average shares — diluted(2)		117,275		106,151		117,781		102,665

(1) These non-GAAP condensed consolidated statements of operations exclude depreciation of property and equipment; stock-based compensation expense; amortization of intangible assets; interest income and other, net; interest expense; income taxes and certain other miscellaneous items that were not classified in the foregoing categories and are identified below.

During the three months ended June 30, 2006, the miscellaneous excluded items consisted of (a) other acquisition-related charges of $2.2 million related to the operations of ESP Pharma Holding Company, Inc. prior to the Company’s acquisition of ESP Pharma on March 23, 2005, primarily product returns, as well as returns of Retavase for sales made prior to the Company’s acquisition of the rights to the product from Centocor, Inc. on the same date, and (b) an asset impairment charge of $0.9 million for the write-off of an acquired technology. During the three months ended June 30, 2005, the miscellaneous excluded items consisted of other acquisition-related charges of $3.2 million.

During the six months ended June 30, 2006, the miscellaneous excluded items consisted of (a) other acquisition-related charges of $3.3 million, (b) an asset impairment charge of $0.9 million and (c) a $4.1 million charge for payments to Wyeth in consideration of Wyeth’s consent to the Company’s transfer of the Company’s rights to four off-patent products, originally acquired from ESP Pharma, that the Company sold in the first quarter of 2006. During the six months ended June 30, 2005, the miscellaneous excluded items consisted of (a) other acquisition-related charges of $3.2 million and (b) a $79.4 million charge for acquired in-process research and development related to the ESP Pharma acquisition.

(2) These weighted average shares exclude 12.4 million shares and 10.6 million shares of common stock underlying the convertible notes we issued in July 2003 and February 2005, respectively.

PDL BIOPHARMA, INC.

RECONCILIATION OF NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO GAAP

(in thousands, except per share amounts)

(unaudited)

	Three Months Ended June 30, 2006
			Adjustments
	Non-GAAP Results		Amortization of Intangible Assets			Other Excluded Items			Depreciation of Property and Equipment			Stock-Based Compensation Expenses			GAAP Results As Reported
REVENUES:
Product sales, net	$	39,039	$	—		$	—		$	—		$	—		$	39,039
Royalties		54,021		—			—			—			—			54,021
License, collaboration and other		11,264		—			—			—			—			11,264
Total revenues		104,324		—			—			—			—			104,324
COSTS AND EXPENSES:
Cost of product sales		10,917		10,565			—			—			—			21,482
Research and development		50,979		487			—			7,168			3,253			61,887
Selling, general and administrative		22,352		—			—			635			2,349			25,336
Non-GAAP costs and expenses		84,248
Depreciation of property and equipment		—		—			7,803			(7,803	)		—			—
Stock-based compensation		—		—			5,602			—			(5,602	)		—
Acquired in-process research and development		—		—			—			—			—			—
Other acquisition-related charges		—		—			2,177			—			—			2,177
Asset impairment charge		—		—			900			—			—			900
Total costs and expenses				11,052			16,482			—			—			111,782
Operating loss				(11,052	)		(16,482	)		—			—			(7,458	)
Interest income and other, net		—		—			4,064			—			—			4,064
Interest expense		—		—			(2,622	)		—			—			(2,622	)
Income (loss) before income taxes		20,076		(11,052	)		(15,040	)		—			—			(6,016	)
Income tax expense		—		—			118			—			—			118
Net income (loss)	$	20,076	$	(11,052	)	$	(15,158	)	$	—		$	—		$	(6,134	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.18													$	(0.05	)
Weighted average shares — basic		113,539														113,539
Diluted	$	0.17													$	(0.05	)
Weighted average shares — diluted		117,275														113,539

	Three Months Ended June 30, 2005
			Adjustments
	Non-GAAP Results		Amortization of Intangible Assets			Other Excluded Items			Depreciation of Property and Equipment			Stock-Based Compensation Expenses			GAAP Results As Reported
REVENUES:
Product sales, net	$	38,552	$	—		$	—		$	—		$	—		$	38,552
Royalties		37,528		—			—			—			—			37,528
License, collaboration and other		4,888		—			—			—			—			4,888
Total revenues		80,968		—			—			—			—			80,968
COSTS AND EXPENSES:
Cost of product sales		8,230		11,905			—			—			—			20,135
Research and development		36,407		487			—			3,436			9			40,339
Selling, general and administrative		19,222		—			—			415			169			19,806
Non-GAAP costs and expenses		63,859
Depreciation of property and equipment		—		—			3,851			(3,851	)		—			—
Stock-based compensation		—		—			178			—			(178	)		—
Acquired in-process research and development		—		—			—			—			—			—
Other acquisition-related charges		—		—			3,207			—			—			3,207
Total costs and expenses				12,392			7,236			—			—			83,487
Operating income (loss)				(12,392	)		(7,236	)		—			—			(2,519	)
Interest income and other, net		—		—			1,873			—			—			1,873
Interest expense		—		—			(2,709	)		—			—			(2,709	)
Income (loss) before income taxes		17,109		(12,392	)		(8,072	)		—			—			(3,355	)
Income tax expense		—		—			65			—			—			65
Net income (loss)	$	17,109	$	(12,392	)	$	(8,137	)	$	—		$	—		$	(3,420	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.16													$	(0.03	)
Weighted average shares—basic		103,705														103,705
Diluted	$	0.16													$	(0.03	)
Weighted average shares—diluted		106,151														103,705

PDL BIOPHARMA, INC.

RECONCILIATION OF NON-GAAP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS TO GAAP

(in thousands, except per share amounts)

(unaudited)

	Six Months Ended June 30, 2006
			Adjustments
	Non-GAAP Results		Amortization of Intangible Assets			Other Excluded Items			Depreciation of Property and Equipment			Stock-Based Compensation Expenses			GAAP Results As Reported
REVENUES:
Product sales, net	$	76,586	$	—		$	—		$	—		$	—		$	76,586
Royalties		97,991		—			—			—			—			97,991
License, collaboration and other		20,959		—			—			—			—			20,959
Total revenues		195,536		—			—			—			—			195,536
COSTS AND EXPENSES:
Cost of product sales		23,311		21,130			—			—			—			44,441
Research and development		102,549		974			—			14,256			5,879			123,658
Selling, general and administrative		46,352		—			4,123			1,151			5,869			57,495
Non-GAAP costs and expenses		172,212
Depreciation of property and equipment		—		—			15,407			(15,407	)		—			—
Stock-based compensation		—		—			11,748			—			(11,748	)		—
Acquired in-process research and development		—		—			—			—			—			—
Other acquisition-related charges		—		—			3,295			—			—			3,295
Asset impairment charge		—		—			900			—			—			900
Total costs and expenses				22,104			35,473			—			—			229,789
Operating loss				(22,104	)		(35,473	)		—			—			(34,253	)
Interest income and other, net		—		—			7,394			—			—			7,394
Interest expense		—		—			(5,272	)		—			—			(5,272	)
Income (loss) before income taxes		23,324		(22,104	)		(33,351	)		—			—			(32,131	)
Income tax expense		—		—			233			—			—			233
Net income (loss)	$	23,324	$	(22,104	)	$	(33,584	)	$	—		$	—		$	(32,364	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.21													$	(0.29	)
Weighted average shares — basic		113,006														113,006
Diluted	$	0.20													$	(0.29	)
Weighted average shares — diluted		117,781														113,006

	Six Months Ended June 30, 2005
			Adjustments
	Non-GAAP Results		Amortization of Intangible Assets			Other Excluded Items			Depreciation of Property and Equipment			Stock-Based Compensation Expenses			GAAP Results As Reported
REVENUES:
Product sales, net	$	39,500	$	—		$	—		$	—		$	—		$	39,500
Royalties		70,692		—			—			—			—			70,692
License, collaboration and other		9,591		—			—			—			—			9,591
Total revenues		119,783		—			—			—			—			119,783
COSTS AND EXPENSES:
Cost of product sales		8,307		12,965			—			—			—			21,272
Research and development		67,752		1,136			—			6,564			148			75,600
Selling, general and administrative		26,732		14			—			548			178			27,472
Non-GAAP costs and expenses		102,791
Depreciation of property and equipment		—		—			7,112			(7,112	)		—			—
Stock-based compensation		—		—			326			—			(326	)		—
Acquired in-process research and development		—		—			79,417			—			—			79,417
Other acquisition-related charges		—		—			3,207			—			—			3,207
Total costs and expenses				14,115			90,062			—			—			206,968
Operating income (loss)				(14,115	)		(90,062	)		—			—			(87,185	)
Interest income and other, net		—		—			4,808			—			—			4,808
Interest expense		—		—			(4,851	)		—			—			(4,851	)
Income (loss) before income taxes		16,992		(14,115	)		(90,105	)		—			—			(87,228	)
Income tax expense		—		—			87			—			—			87
Net income (loss)	$	16,992	$	(14,115	)	$	(90,192	)	$	—		$	—		$	(87,315	)
NET INCOME (LOSS) PER SHARE:
Basic	$	0.17													$	(0.87	)
Weighted average shares—basic		100,230														100,230
Diluted	$	0.17													$	(0.87	)

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEET DATA

(in thousands)

(unaudited)

	June 30, 2006		December 31, 2005
Cash, cash equivalents, marketable securities and restricted investment	$	414,343	$	333,922
Total assets	$	1,181,647	$	1,163,154
Total stockholders’ equity	$	539,443	$	526,065

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA

(in thousands)

(unaudited)

	Six Months Ended June 30,
	2006			2005
Net loss	$	(32,364	)	$	(87,315	)
Adjustments to reconcile net loss to net cash provided by operating activities		51,534			102,091
Changes in assets and liabilities		24,469			(17,200	)
Net cash provided by (used in) operating activities	$	43,639		$	(2,424	)